TGFB1 single-nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. In regard to Peters et al. (Int J Radiat Oncol Biol Phys 2008;70:752-759).
Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):960; author reply 960-1.
Comment on:
Langsenlehner T, Kapp KS, Langsenlehner U.
Related Articles:- In regard to Selek et al. erectile dysfunction and radiation dose to penile base structures: a lack of correlation. IJROBP 2004;59:1039-1046.
- The need and prospect of individualized external beam radiotherapy dose escalation beyond 80 gy to treat prostate cancer: in regard to Eade et al. (Int J. Radiat. Oncol. Biol. Phys. 2007;68:682-689).
- Is it time to change the standard of care from CT to MRI for defining the apex of the prostate to accomplish potency-sparing radiotherapy?
- Selling sickness: the pharmaceutical industry and disease mongering.
- Vessel-sparing prostate radiotherapy: dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRI.
0 comments
Kick things off by filling out the form below.
Leave a Comment